Home LiteratureArticle Details
PMID: 17169248 Published · ppublish English Journal Article Review

Modifying the anti-inflammatory effects of high-density lipoprotein.

Current atherosclerosis reports ·Vol. 9 ·No. 1 ·2007-01-00 ·Pages 57-63

Ansell BJ, Fonarow GC, Navab M, Fogelman AM

Abstract

The anti-inflammatory effects of high-density lipoproteins (HDL) are well documented and include inhibition of low-density lipoprotein (LDL) oxidation, reduction of inflammatory cytokines and vascular leukocyte adhesion molecules, and participation in innate immunity. However, certain conditions, including coronary disease, diabetes mellitus, systemic inflammation, and a diet high in saturated fat, are associated with modification of HDL such that it paradoxically enhances LDL oxidation and/or vascular inflammation. Treatment with statins and/or apolipoprotein A1 mimetic peptides improves HDL's anti-inflammatory functions, and these as well as other medications may represent a novel pathway through which to target atherosclerosis.

MeSH Terms
Humans Inflammation/metabolism,pathology,prevention & control Inflammation Mediators/physiology Lipoproteins, HDL/adverse effects,physiology
Chemicals
Inflammation Mediators Lipoproteins, HDL
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Ansell Benjamin J
Department of Medicine, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA. [email protected]
Fonarow Gregg C
Navab Mohamad
Fogelman Alan M
References (46)
46 references, click to expand
  1. Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL.
    Atheroscler Suppl. 2002 Dec;3(4):23-30 PMID: 12573360
  2. Oxidized lipoproteins including HDL and their lipid peroxidation products inhibit TNF-alpha secretion by THP-1 human macrophages.
    Free Radic Biol Med. 1997;23(4):658-67 PMID: 9215811
  3. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages.
    J Biol Chem. 2005 Jan 7;280(1):38-47 PMID: 15498770
  4. Regulation of reverse cholesterol transport and clinical implications.
    Am J Cardiol. 2003 Aug 18;92 (4A):42J-49J PMID: 12957326
  5. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function.
    J Am Coll Cardiol. 2006 Aug 15;48(4):715-20 PMID: 16904539
  6. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity.
    Free Radic Res. 2003 Jan;37(1):77-83 PMID: 12653220
  7. The double jeopardy of HDL.
    Ann Med. 2005;37(3):173-8 PMID: 16019715
  8. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.
    Diabetologia. 2005 Mar;48(3):529-38 PMID: 15729582
  9. High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis.
    Shock. 2004 Apr;21(4):342-51 PMID: 15179135
  10. Statins downregulate myeloperoxidase gene expression in macrophages.
    Biochem Biophys Res Commun. 2005 Jun 3;331(2):442-51 PMID: 15850779
  11. Structural modifications of HDL and functional consequences.
    Atherosclerosis. 2006 Jan;184(1):1-7 PMID: 16157342
  12. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL.
    Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2226-33 PMID: 10479666
  13. Endothelial and antithrombotic actions of HDL.
    Circ Res. 2006 Jun 9;98(11):1352-64 PMID: 16763172
  14. The inflammation: lipoprotein cycle.
    Atheroscler Suppl. 2005 May;6(2):15-20 PMID: 15823492
  15. High-density lipoprotein function recent advances.
    J Am Coll Cardiol. 2005 Nov 15;46(10):1792-8 PMID: 16286161
  16. Glycation impairs high-density lipoprotein function.
    Diabetologia. 2000 Mar;43(3):312-20 PMID: 10768092
  17. A new antiinflammatory compound, leumedin, inhibits modification of low density lipoprotein and the resulting monocyte transmigration into the subendothelial space of cocultures of human aortic wall cells.
    J Clin Invest. 1993 Mar;91(3):1225-30 PMID: 8450051
  18. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.
    Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1426-32 PMID: 15845909
  19. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.
    J Clin Invest. 2004 Aug;114(4):529-41 PMID: 15314690
  20. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock.
    Shock. 2003 Dec;20(6):551-7 PMID: 14625480
  21. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Circulation. 2003 Dec 2;108(22):2751-6 PMID: 14638544
  22. Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers.
    J Biol Chem. 1998 Jul 10;273(28):17391-8 PMID: 9651324
  23. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion.
    Circ Res. 2006 Mar 3;98 (4):490-8 PMID: 16439686
  24. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.
    Circulation. 2001 May 8;103(18):2283-8 PMID: 11342478
  25. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.
    JAMA. 1986 Nov 28;256(20):2835-8 PMID: 3773200
  26. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Am J Cardiol. 2003 Jul 15;92(2):152-60 PMID: 12860216
  27. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.
    JAMA. 2003 Nov 5;290(17 ):2292-300 PMID: 14600188
  28. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.
    Circulation. 2002 Jan 22;105(3):290-2 PMID: 11804981
  29. High-density lipoprotein: is it always atheroprotective?
    Curr Atheroscler Rep. 2006 Sep;8(5):405-11 PMID: 16901411
  30. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.
    J Clin Invest. 1990 Apr;85(4):1234-41 PMID: 2318976
  31. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules.
    Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1987-94 PMID: 7583580
  32. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.
    J Lipid Res. 2004 Jul;45(7):1169-96 PMID: 15102878
  33. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
    Nat Clin Pract Cardiovasc Med. 2006 Oct;3(10):540-7 PMID: 16990839
  34. A longitudinal analysis of alteration in lecithin-cholesterol acyltransferase and paraoxonase activities following laparoscopic cholecystectomy relative to other parameters of HDL function and the acute phase response.
    Scand J Immunol. 1998 Oct;48(4):419-24 PMID: 9790313
  35. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population.
    Clin Chem. 2003 Sep;49(9):1491-7 PMID: 12928230
  36. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1.
    J Lipid Res. 2000 Sep;41(9):1481-94 PMID: 10974056
  37. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis.
    Arthritis Rheum. 2006 Aug;54(8):2541-9 PMID: 16868975
  38. Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice.
    Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1583-8 PMID: 12855483
  39. HDL and arteriosclerosis: beyond reverse cholesterol transport.
    Atherosclerosis. 2002 Mar;161(1):1-16 PMID: 11882312
  40. Simvastatin decreases aldehyde production derived from lipoprotein oxidation.
    Am J Cardiol. 1999 Mar 15;83(6):846-51 PMID: 10190397
  41. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity.
    Acta Diabetol. 2001 Dec;38(4):163-9 PMID: 11855794
  42. Acute-phase proteins and other systemic responses to inflammation.
    N Engl J Med. 1999 Feb 11;340(6):448-54 PMID: 9971870
  43. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Circulation. 2004 Jun 29;109(25):3215-20 PMID: 15197147
  44. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients.
    Nephrol Dial Transplant. 2000 Mar;15(3):389-95 PMID: 10692526
  45. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice.
    Circ Res. 2005 Sep 16;97(6):524-32 PMID: 16100046
  46. Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure.
    J Biol Chem. 2006 Mar 3;281(9):5515-21 PMID: 16407233
Article Info
Journal
Current atherosclerosis reports
Abbr.
Curr Atheroscler Rep
ISSN
1523-3804
DOI
10.1007/BF02693941
Email
[email protected]
Published
2007-01-00
Pages
57-63
Language
English
Region
United States
NLM ID
100897685
Subset
IM
External Links
PubMed source DOI: 10.1007/BF02693941 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2